Why Motilium pharmacy carts are not a U.S. fill
Search results for “buy Motilium online” and “domperidone online pharmacy” are crowded with Canadian and other foreign storefronts. Those pages answer a shopping query. They do not create a state-licensed U.S. pharmacy fill for an unapproved human drug.
FDA states that distributing any domperidone-containing products for human use in the U.S. is illegal in general, with limited exceptions such as use under an investigational new drug application. Compounded products containing domperidone do not meet the conditions under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act, so they cannot be legally compounded for humans under those sections.
FDA’s guide to buying medicines online still applies as a filter for any pharmacy claim you see: unsafe internet pharmacies often sell medicines without requiring a prescription, and a lawful seller for an approved U.S. medicine needs a prescription, a physical U.S. address and phone, a licensed pharmacist, and a state board of pharmacy license you can check through BeSafeRx. A Motilium cart that skips those tests — or that ships an unapproved product into the country as if it were an ordinary refill — is the wrong door for this molecule.
When a U.S. physician can request domperidone under expanded access
For some patients, FDA describes a physician-supervised path: an expanded-access investigational new drug application. Patients 12 years of age and older with certain gastrointestinal conditions who have failed standard therapies — gastroesophageal reflux disease with upper GI symptoms, gastroparesis, or chronic constipation — may be able to receive treatment that way. The treating clinician downloads the Domperidone Packet, arranges supplier authorization and IRB/informed-consent steps, and may use Form FDA 3926 for a single-patient request.
That paperwork is not the same as clicking “add to cart” on a foreign Motilium page. It is also not a guarantee that tablets are available. FDA notified clinicians that the then-current supplier would no longer distribute domperidone for expanded-access use after September 2025 once supply was exhausted, and that a new supplier would be required for a new IND — including import requirements if the product comes from outside the United States. Ask the prescribing clinician what is open now; this desk cannot invent a current warehouse.
QT risk, CYP3A4 stops, and the 30 mg day frame
Even where domperidone is marketed, labels treat the heart as a hard limit. Canadian product labeling for domperidone maleate tablets contraindicates use in people with known QT prolongation, significant electrolyte disturbance, congestive heart failure, or moderate-to-severe liver impairment, and contraindicates co-administration with QT-prolonging drugs and with potent CYP3A4 inhibitors such as azole antifungals (for example ketoconazole), the macrolide antibiotic erythromycin, HIV protease inhibitors, and nefazodone. The same monographs frame higher cardiac risk with daily doses above 30 mg and recommend the lowest effective dose for the shortest necessary duration — commonly up to 10 mg three times daily within that 30 mg ceiling unless a specialist plan says otherwise.
FDA’s U.S. consumer and clinician pages add that domperidone has been associated with serious cardiac adverse events, including arrhythmias, cardiac arrest, and sudden death. If a medicine list already includes a strong CYP3A4 inhibitor or another QT-prolonging drug, that collision is a reason to stop the Motilium fantasy before anyone talks about import paperwork.
Lactation is not an approved use
FDA states that domperidone is not approved in any country to stimulate lactation or enhance breast milk production. The agency has published cardiac warnings for lactation use and has reviewed neuropsychiatric adverse events after sudden discontinuation or tapering when the drug was used for milk supply. Domperidone taken by a lactating person is excreted in breast milk and can expose an infant to unknown risks. A buy-search for Motilium aimed at breastfeeding is not the same job as an expanded-access request for severe GI motility disease after other therapies fail.
U.S. prokinetic options are a different conversation
When nausea, delayed emptying, or reflux symptoms need a prokinetic in the United States, clinicians usually work inside FDA-approved options and labeled limits for those products. That conversation is not a one-click swap for Motilium 10 mg from a foreign cart, and this page does not treat any approved U.S. medicine as “the same as Motilium.” If standard therapies have already failed and a specialist is considering investigational access, that decision stays with the clinician and the IND process above.
Motilium and domperidone: questions before you click a cart
### Is Motilium the same as domperidone?
Yes. Motilium is a brand name used internationally for domperidone. In the United States there is still no FDA-approved Motilium or generic domperidone tablet for routine sale.
### Can I order Motilium from a Canadian pharmacy instead?
A Canadian or other foreign Motilium listing is not a substitute for a U.S. approved fill. FDA’s general rule is that distributing domperidone for human use in the U.S. is illegal outside limited exceptions such as an expanded-access IND.
### How do patients in the U.S. get domperidone legally?
Through a physician who submits an expanded-access IND for an eligible GI condition after standard therapies fail — not through an ordinary online checkout. Confirm current supplier status with that clinician, because FDA reported a 2025 interruption in the prior expanded-access supply chain.
### Can a compounding pharmacy make domperidone?
No under the usual 503A/503B compounding conditions. FDA states that domperidone-containing products cannot be legally compounded for humans under those sections.
### Is Motilium used to increase breast milk?
That is not an approved use in any country, per FDA. Cardiac risk and reported neuropsychiatric effects after abrupt stop or taper make lactation Motilium carts a particularly poor match for a “buy online” shortcut.
If the buy query brought you here hoping for a cart, the useful next step is a clinician conversation about approved U.S. options — or, when those have already failed for a qualifying GI diagnosis, about whether expanded access is even open — not a foreign Motilium checkout that pretends the U.S. shelf already exists.